Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of StemRIM Inc.. A complete text table follows the diagram.
StemRIM reported no operating revenue; JPY749M of R&D represented 75% of operating expenses as Redasemtide advanced and the next pipeline entered preclinical and partnering work.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Research & development expenses | 1 | 749M | 75.4% of reported total |
| Selling, general & administrative expenses | 1 | 244M | 24.6% of reported total |
| Operating expenses | 2 | 993M | Reported six-month total · ¥993M |
| Operating loss | 2 | 993M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 2.0B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Research & development expenses | Operating expenses | 749M |
| Selling, general & administrative expenses | Operating expenses | 244M |
| Operating expenses | Operating costs & expenses | 993M |
| Operating loss | Operating costs & expenses | 993M |